微针经皮递送生物大分子药物的研究进展  

Advances in Microneedle-Mediated Transdermal Delivery of Biomacromolecular Drugs

作　　者：武文涛 周纯娴 吴传斌 潘昕[1] 彭婷婷 WU Wentao;ZHOU Chunxian;WU Chuanbin;PAN Xin;PENG Tingting(School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;College of Pharmacy,Jinan University,Guangzhou 510632,China)

机构地区：[1]中山大学药学院,广东广州510006 [2]暨南大学药学院,广东广州511443

出　　处：《药学进展》2024年第4期254-268,共15页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.82104071,No.82330112,No.82373803);广东省中医药局科研项目(No.20231084);广东省自然科学杰出青年项目(No.2022B1515020085)。

摘　　要：生物大分子药物已被公认为是21世纪药物研发中最具发展前景的领域,但其递药方式单一,难以满足临床的治疗需求。微针作为新型经皮给药系统,能直接穿透角质层,将药物递送到皮肤组织进行吸收,具有无痛给药、高效递药和安全性高等优势。近年来,微针经皮递送蛋白质、多肽、核酸和疫苗等生物大分子药物的研究日益增多,在理论和技术方面均取得了重大进展。综述总结了微针递送生物大分子药物在传染病、糖尿病和肿瘤等重大疾病治疗中的应用,剖析了其在实际应用和临床转化过程中所面临的技术瓶颈,最后对微针技术的未来发展进行了展望,以期能为微针递送生物大分子药物的研发和临床转化提供参考。Biomacromolecular drugs have been recognized as the most promising field of drug research and development in the 21st century;however,their mode of delivery is too simple,making it difficult to meet the clinical therapeutic requirements.As a novel transdermal drug delivery system,microneedles can directly penetrate the stratum corneum and deliver drugs to the skin tissues for absorption,with the advantages of painlessness,high efficiency and high safety in delivery.In recent years,more and more studies have been conducted on the microneedle-mediated transdermal delivery of biomacromolecular drugs such as proteins,peptides,nucleic acids,and vaccines,and great progress has been made in theory and technology.This review summarizes the application of biomacromolecular drugs delivered by microneedles in the treatment of such major threats as infectious diseases,diabetes and tumor,and analyzes the technological bottlenecks involved in their practical application and clinical translation,with an outlook on the future development of microneedle technology,in the hope of providing some insight for the development and clinical translation of microneedle-mediated delivery of biomacromolecular drugs.

关 键 词：微针 生物大分子药物 治疗应用 技术瓶颈 临床转化 

分 类 号：R944.9[医药卫生—药剂学]